Mabwell 9MW2821 Combination Therapy Data to Be Presented at ASCO 2026 for Urothelial Carcinoma Treatment

Key Takeaways

• Mabwell will present two clinical studies of 9MW2821 combined with toripalimab for urothelial carcinoma at ASCO 2026
• The Nectin-4-targeting ADC combination represents a potential new treatment option for bladder cancer patients
• Presentations scheduled for May 29-June 2, 2026 at the American Society of Clinical Oncology Annual Meeting in Chicago

---

Shanghai-based biopharmaceutical company Mabwell (688062.SH) announced that clinical data from two studies evaluating its investigational cancer treatment 9MW2821 in combination with toripalimab will be featured at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

The presentations, scheduled for May 29 to June 2, 2026 in Chicago, will showcase the latest results from clinical trials testing the combination therapy in patients with urothelial carcinoma, the most common form of bladder cancer.

Novel ADC Combination Approach

9MW2821 is a Nectin-4-targeting antibody-drug conjugate (ADC) developed by Mabwell. The experimental treatment is being studied in combination with toripalimab, an anti-PD-1 immunotherapy, representing a dual-mechanism approach to cancer treatment that combines targeted therapy with immune checkpoint inhibition.

Urothelial carcinoma affects the lining of the bladder and other parts of the urinary system, with limited treatment options available for advanced stages of the disease. The combination of an ADC with an immunotherapy agent represents a promising therapeutic strategy that could potentially improve outcomes for patients with this challenging cancer type.

Clinical Development Milestone

The acceptance of two presentations at ASCO 2026 - one oral presentation and one poster - indicates the significance of the clinical data generated from Mabwell’s studies. ASCO’s Annual Meeting is considered the premier global oncology conference, where groundbreaking cancer research and treatment advances are shared with the international medical community.

Mabwell describes itself as an innovation-driven biopharmaceutical company with a fully integrated industry chain, positioning the company to advance novel cancer treatments from research through clinical development. The company’s focus on ADC technology aligns with the growing interest in this therapeutic class for treating various cancer types.

The upcoming presentations will provide the medical community and investors with important insights into the potential efficacy and safety profile of this combination approach for urothelial carcinoma patients.

---

Frequently Asked Questions

What is 9MW2821 and how does it work?

9MW2821 is a Nectin-4-targeting antibody-drug conjugate (ADC) that delivers chemotherapy directly to cancer cells expressing the Nectin-4 protein, potentially reducing side effects while maximizing anti-tumor activity.

When will this combination therapy be available to patients?

The treatment is currently in clinical trials. Availability to patients will depend on successful completion of clinical studies and regulatory approval, which typically takes several years.

How does this compare to current urothelial carcinoma treatments?

Current treatments include chemotherapy, immunotherapy, and targeted therapies. This ADC-immunotherapy combination represents a novel dual-mechanism approach that could potentially offer improved efficacy over single-agent treatments.